



## Verastem Oncology to Present at Upcoming Investor Conferences

September 27, 2018

BOSTON--(BUSINESS WIRE)--Sep. 27, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor conferences:

- The Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00pm EDT in New York City, NY, USA
- The Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018 at 8:00am EDT in New York City, NY, USA

A live webcast of each presentation will be available on the investors section of the Company's website at [www.verastem.com](http://www.verastem.com). An archived presentation will be available for 90 days.

### About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it's personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin's lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit [www.verastem.com](http://www.verastem.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180927005885/en/>

Source: Verastem, Inc.

#### *Verastem Oncology:*

Brian Sullivan, +1 781-469-1636  
Senior Director, Corporate Development  
[bsullivan@verastem.com](mailto:bsullivan@verastem.com)

or

#### *Media:*

FleishmanHillard  
Adam Silverstein, +1 917-697-9313  
[media@verastem.com](mailto:media@verastem.com)

or

#### *Investors:*

Argot Partners  
Joseph Rayne, +1 617-340-6075  
[joseph@argotpartners.com](mailto:joseph@argotpartners.com)